Avasopasem manganese is under clinical development by Galera Therapeutics and currently in the Phase II and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Avasopasem manganese’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Oral Mucositis took place on 26 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Avasopasem manganese Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Avasopasem manganese overview

Avasopasem manganese is under development for the treatment of cancer and head and neck squamous cell carcinoma, locally advanced pancreatic adenocarcinoma, radiation-induced esophagitis in patients with lung cancer. It is administered by intravenous infusion route. It is a small molecule enzyme mimetic that both attacks tumors and protects normal tissues from other cancer therapies. It mimics the activity of superoxide dismutase. The drug candidate was also under development for the treatment of arthritis.

It was under development for radiation-chemotherapy-induced oral mucositis in head and neck cancer patients

It was under development for the treatment of Coronavirus Disease 2019 (COVID-19).

Galera Therapeutics overview

Galera Therapeutics (Galera) is a clinical-stage biotechnology company. It focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its pipeline portfolio includes Avasopasem (GC4419), Rucosopasem (GC4711), clinical trials and key publications. Galera GC4419 is a small molecule enzyme mimetic that quickly converts superoxide-free radical molecules to hydrogen peroxide and oxygen which reduces the incidence, severity, and duration of severe oral mucositis. The company’s research and development unit concentrates on protection from normal tissue damage and direct anti-cancer therapy. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.

Quick View Avasopasem manganese LOA Data

Report Segments
  • Innovator
Drug Name
  • Avasopasem manganese
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
  • Musculoskeletal Disorders
  • Oncology
  • Toxicology
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.